In the last 5 years, EMA approved the first six CAR-T autologous cell products targeting CD19 or B cell maturation antigen (BCMA) for the treatment of r/r B cell malignancies, such as acute lymphoblastic leukaemia, large B-cell lymphoma, follicular lymphoma, multiple myeloma (Table 2). This evidence concerns the gene TNFRSF17 and acute lymphoblastic leukemia.